GLP-1 Peptide Synthesis CDMO Market Opportunities Driven by Generics Biosimilars and Post Patent Expiry Demand

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “GLP-1 Peptide Synthesis CDMO Market”-, By Synthesis Technology (Solid-Phase Peptide Synthesis (SPPS), Liquid-Phase Peptide Synthesis (LPPS), Group-Assisted Purification Peptide Synthesis (GAP-PS), Hybrid Technology, Recombinant DNA Technology), By Service Type (Analytical and Process Development, Large-Scale Production, Custom Peptide Synthesis, Peptide Modification, Purification Technology, Formulation Development, Regulatory Support, Packaging and Labeling, Pre-Formulation and Registration Batches), By Scale of Operation (Clinical-Scale Manufacturing, Commercial-Scale Manufacturing, Pilot-Scale Manufacturing), By End-User(Pharmaceutical Companies, Biotechnology Companies, Research Institutions, and Global Forecasts, 2025-2034 And Segment Revenue and Forecast To 2034.” 

Global GLP-1 Peptide Synthesis CDMO Market Size is predicted to grow at a 12.7 % CAGR during the forecast period for 2025-2034.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/3105

A GLP-1 peptide synthesis Contract Development and Manufacturing Organization (CDMO) is a specialized partner providing comprehensive support for the development, synthesis, and GMP-compliant production of Glucagon-Like Peptide-1 (GLP-1) analogues. These synthetic peptides replicate the physiological activity of the natural GLP-1 hormone, which is pivotal in managing type 2 diabetes and obesity through the stimulation of insulin secretion and regulation of blood glucose levels.

CDMOs offer pharmaceutical and biotechnology companies’ expertise in both solid-phase peptide synthesis (SPPS) and liquid-phase peptide synthesis (LPPS), ensuring the production of high-purity peptides with consistent quality. The processes often involve chemical modifications—such as fatty acid conjugation—to enhance peptide half-life, alongside stringent control over folding, bioactivity, stability, and regulatory compliance.

The increasing technical complexity of peptide manufacturing, substantial capital requirements, and the need for specialized expertise are driving pharmaceutical companies to outsource GLP-1 peptide production to CDMOs. Recent innovations in SPPS and LPPS methods have enhanced process efficiency, scalability, and yield.

Moreover, the integration of artificial intelligence and machine learning is transforming peptide development, enabling AI-driven design strategies to optimize receptor activation profiles in GLP-1 analogues, as demonstrated by companies such as ImmunoPrecise Antibodies, which are developing analogues with improved efficacy relative to established therapies like semaglutide.

The expected patent expirations of key GLP-1 therapeutics, including semaglutide, are further increasing demand for generic and biosimilar peptide APIs. In response, CDMOs are expanding production capacities and adopting advanced purification technologies, such as high-performance liquid chromatography (HPLC) and mass spectrometry.

Additionally, the growing number of small and mid-sized biotechnology firms lacking in-house peptide synthesis capabilities is driving demand for CDMOs that can provide flexible, small-scale manufacturing solutions suitable for preclinical research and clinical development.

List of Prominent Players in the GLP-1 Peptide Synthesis CDMO Market:

• Bachem Holding AG
• CordenPharma
• PolyPeptide Group
• AmbioPharm
• CPC Scientific
• CSBio
• Creative Peptides
• Lonza
• Aurisco Pharmaceutical
• Hybio Pharmaceuticals
• Chinese Peptide Company
• Neuland Laboratories
• Divis Laboratories
• Supriya Lifescience
• Allsino Pharmaceutical Co. Ltd

Expert Knowledge, just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

Market Dynamics

Drivers:

The rising global prevalence of type 2 diabetes and obesity is driving strong demand for GLP-1 receptor agonists, including semaglutide and tirzepatide, which are widely prescribed for glycemic management and weight control.

Due to the technical complexity and high costs associated with peptide synthesis, pharmaceutical companies are increasingly relying on Contract Development and Manufacturing Organizations (CDMOs) to optimize production efficiency and leverage specialized expertise.

CDMOs offer end-to-end services spanning early-stage process development to large-scale commercial manufacturing, establishing themselves as strategic partners for both multinational pharmaceutical companies and emerging biotechnology firms.

Advances in solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), and automation are enhancing production scalability, efficiency, and reproducibility.

Additionally, the anticipated expiration of patents for leading GLP-1 therapeutics, such as semaglutide, is stimulating growth in the generics and biosimilars market. In response, CDMOs are expanding manufacturing capabilities to deliver high-quality, bioequivalent peptide therapeutics that meet escalating global demand.

Challenges:

Despite favorable market conditions, large-scale peptide synthesis remains capital-intensive and technically challenging. High costs of raw materials, complex synthetic protocols, and the need for specialized reagents contribute to overall production expenses.

Furthermore, the structural complexity of GLP-1 analogues often results in low purification yields, complicating manufacturing and limiting cost efficiency. These challenges underscore the need for continuous investment in process innovation, purification optimization, and advanced synthesis technologies to improve yield, quality, and operational performance.

Regional Trends:

North America is projected to maintain a dominant share of the GLP-1 peptide synthesis CDMO market over the forecast period, supported by a mature pharmaceutical manufacturing ecosystem, a robust regulatory framework, and strong clinical demand for GLP-1-based therapies.

The United States, in particular, serves as a global hub for drug development and commercialization and represents one of the largest markets for GLP-1 receptor agonists. The presence of experienced CDMOs with GMP-compliant facilities and adherence to FDA standards further strengthens the region’s leadership in peptide contract manufacturing.

Conversely, the Asia-Pacific region is expected to register the fastest growth, driven by cost-competitive manufacturing capabilities, expanding healthcare infrastructure, and increasing regional demand for diabetes and obesity therapeutics. Countries such as China, India, and Japan are investing heavily in biopharmaceutical infrastructure and advanced peptide production technologies, positioning the region as an increasingly important hub for global CDMO services in peptide synthesis.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/3105

Recent Developments:

• In Aug 2024, PolyPeptide, has teamed up to work on creating a GLP-1 agonist using a more environmentally friendly production process. The initiative will operate for the next 12 months after receiving a 1 million SEK prize from Sweden’s innovation agency, Vinnova.  GLP-1 receptor agonist medicines are in high demand worldwide for treating diabetes and obesity.  The production of peptides typically involves a high process mass intensity and the extensive use of dangerous solvents like N, N-dimethylformamide (DMF).
• In Sept2023, CordenPharma was pleased to announce the opening of expanded commercial peptide production capacity at CordenPharma Colorado, the world’s biggest solid-phase peptide synthesis (SPPS) manufacturing plant, with recently renovated facilities. Beginning capital investments in early 2023, CordenPharma has successfully finished many facilities upgrades and modernizations that have improved the productivity and efficiency of SPPS peptide production. This has given the company more capacity to serve both present and future clients across a growing base of pharmaceutical innovators.

Segmentation of GLP-1 Peptide Synthesis CDMO Market.

Global GLP-1 Peptide Synthesis CDMO Market – By Synthesis Technology

• Solid-Phase Peptide Synthesis (SPPS)
• Liquid-Phase Peptide Synthesis (LPPS)
• Group-Assisted Purification Peptide Synthesis (GAP-PS)
• Hybrid Technology
• Recombinant DNA Technology

Global GLP-1 Peptide Synthesis CDMO Market – By Service Type

• Analytical and Process Development
• Large-Scale Production
• Custom Peptide Synthesis
• Peptide Modification
• Purification Technology
• Formulation Development
• Regulatory Support
• Packaging and Labeling
• Pre-Formulation and Registration Batches

Global GLP-1 Peptide Synthesis CDMO Market – By Scale of Operation

• Clinical-Scale Manufacturing
• Commercial-Scale Manufacturing
• Pilot-Scale Manufacturing

Global GLP-1 Peptide Synthesis CDMO Market – By End-User

• Pharmaceutical Companies
• Biotechnology Companies
• Research Institutions

Global GLP-1 Peptide Synthesis CDMO Market – By Region

North America-

• The US
• Canada

Europe-

• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe

Asia-Pacific-

• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific

Latin America-

• Brazil
• Argentina
• Mexico
• Rest of Latin America

 Middle East & Africa-

• GCC Countries
• South Africa
• Rest of the Middle East and Africa

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Disclaimer: The iCrowdNewswire provides distribution services for Research Marketing reports, however, it does not assume any responsibility for the content (facts, opinions, photos, or any other part of it) of the reports.  All responsibility of the content is with the publisher of the report.

Tags: GLP-1 Peptide Synthesis CDMO Market